{
    "clinical_study": {
        "@rank": "102711", 
        "brief_summary": {
            "textblock": "To determine if a pharmacokinetic (blood level) interaction exists between zidovudine (AZT)\n      and oxazepam in the HIV-infected patient. Benzodiazepines (such as oxazepam) are among the\n      most frequently prescribed class of drugs and are commonly used therapeutically for patients\n      with chronic disease. This study is important because of the potential for toxicity\n      resulting from a reaction between AZT and benzodiazepines and the likelihood of frequent use\n      of the combination of these drugs in patients with HIV infection."
        }, 
        "brief_title": "The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs\n      and are commonly used therapeutically for patients with chronic disease. This study is\n      important because of the potential for toxicity resulting from a reaction between AZT and\n      benzodiazepines and the likelihood of frequent use of the combination of these drugs in\n      patients with HIV infection.\n\n      Patients are studied to determine oral and intravenous AZT and single oral dose oxazepam\n      pharmacokinetics. Patients then take AZT and oxazepam together to determine if interactions\n      between the drugs occur."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Required:\n\n          -  Stable prescribed dosage of zidovudine (AZT), = or > 500 mg/day.\n\n        Allowed:\n\n          -  Prophylaxis for Pneumocystis carinii pneumonia (PCP) with aerosolized pentamidine.\n\n          -  Erythropoietin.\n\n        Patients must be:\n\n          -  HIV positive by ELISA and Western blot.\n\n          -  Currently taking a stable prescribed dosage of 500 mg/day of zidovudine (AZT).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT)\n             therapy of = or < 600 mg/day.\n\n          -  Significant underlying medical condition that could impair continuous participation\n             in study.\n\n          -  Malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated\n             with an unintentional weight loss of at least 10 percent of body weight).\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Oral contraceptives.\n\n          -  Cytotoxic chemotherapy.\n\n          -  Ganciclovir.\n\n          -  Flucytosine.\n\n          -  Probenecid.\n\n          -  Opiates.\n\n          -  Valproic acid.\n\n          -  Sulfa drugs.\n\n          -  Sucralfate.\n\n          -  Dapsone.\n\n          -  Rifampin.\n\n          -  Antacids within 2 hours of zidovudine (AZT) dose.\n\n          -  Isoniazid.\n\n          -  Ketoconazole.\n\n          -  Pyrimethamine.\n\n          -  Clindamycin.\n\n          -  Aspirin.\n\n          -  Ibuprofen.\n\n          -  Investigational drugs not specifically allowed.\n\n        Patients with the following are excluded:\n\n          -  Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT)\n             therapy of = or < 600 mg/day.\n\n          -  Significant underlying medical condition that could impair continuous participation\n             in study.\n\n          -  Unable to take oral medication reliably.\n\n        Prior Medication:\n\n        Excluded within 30 days of study entry:\n\n          -  Antiretroviral agents other than zidovudine (AZT)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "8", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000661", 
            "org_study_id": "ACTG 124"
        }, 
        "intervention": [
            {
                "intervention_name": "Oxazepam", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxazepam", 
                "Zidovudine"
            ]
        }, 
        "keyword": [
            "Oxazepam", 
            "Drug Evaluation", 
            "Drug Interactions", 
            "Zidovudine"
        ], 
        "lastchanged_date": "August 1, 2008", 
        "link": {
            "description": "Click here for more information about Zidovudine", 
            "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=4"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Palo Alto", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94304"
                }, 
                "name": "Palo Alto Veterans Adm Med Ctr / Stanford Univ"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient", 
        "overall_official": [
            {
                "last_name": "Israelski D", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Blaschke T", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "citation": "Mole LA, Israelski DM, Bubp JL, O'Hanley P, Merigan T, Blaschke T. The pharmacokinetics (PK) of zidovudine (ZDV) and oxazepam (OXA) alone and in combination in the HIV-infected patient (ACTG 124). Int Conf AIDS. 1992 Jul 19-24;8(2):B186 (abstract no PoB 3595)"
            }, 
            {
                "PMID": "8417175", 
                "citation": "Mole L, Israelski D, Bubp J, O'Hanley P, Merigan T, Blaschke T. Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. J Acquir Immune Defic Syndr. 1993 Jan;6(1):56-60."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000661"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1994"
    }, 
    "geocoordinates": {
        "Palo Alto Veterans Adm Med Ctr / Stanford Univ": "37.442 -122.143"
    }
}